A Phase I/II study from 2022 assessed the safety and potential of [64Cu]Cu-Sarcophagine-Bombesin ([64Cu]Cu-SAR-BBN) (Figure 7, 15) PET/CT in re-staging metastatic BC with positive ER/PR expression and negative HER2 expression. This evidence concerns the gene ESR1 and breast cancer.